Neuberger Berman Group’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$272M Buy
9,693,119
+2,331,465
+32% +$62.1M 0.21% 95
2025
Q4
$183M Sell
7,361,654
-1,651,157
-18% -$41.6M 0.14% 165
2025
Q3
$229M Buy
9,012,811
+6,045,763
+204% +$149M 0.17% 124
2025
Q2
$71.9M Buy
2,967,048
+1,054,125
+55% +$24.6M 0.06% 386
2025
Q1
$48.5M Sell
1,912,923
-3,032,970
-61% -$79.4M 0.04% 439
2024
Q4
$131M Sell
4,945,893
-9,001,249
-65% -$244M 0.1% 234
2024
Q3
$404M Buy
13,947,142
+149,492
+1% +$4.36M 0.32% 70
2024
Q2
$386M Sell
13,797,650
-1,454,733
-10% -$40.1M 0.32% 71
2024
Q1
$423M Sell
15,252,383
-2,449,966
-14% -$68M 0.35% 56
2023
Q4
$510M Buy
17,702,349
+666,784
+4% +$20.2M 0.44% 44
2023
Q3
$565M Buy
17,035,565
+3,292,002
+24% +$116M 0.51% 36
2023
Q2
$504M Sell
13,743,563
-54,920
-0.4% -$2.14M 0.45% 42
2023
Q1
$563M Buy
13,798,483
+1,456,337
+12% +$62.9M 0.52% 34
2022
Q4
$632M Sell
12,342,146
-931,535
-7% -$44.7M 0.62% 19
2022
Q3
$581M Buy
13,273,681
+1,061,894
+9% +$51.6M 0.61% 18
2022
Q2
$640M Buy
12,211,787
+2,208,244
+22% +$113M 0.64% 16
2022
Q1
$518M Buy
10,003,543
+499,802
+5% +$25.9M 0.44% 34
2021
Q4
$556M Buy
9,503,741
+119,903
+1% +$5.94M 0.44% 39
2021
Q3
$401M Buy
9,383,838
+828,318
+10% +$36.7M 0.35% 57
2021
Q2
$334M Buy
8,555,520
+3,317,439
+63% +$129M 0.29% 76
2021
Q1
$189M Sell
5,238,081
-1,039,370
-17% -$36.9M 0.18% 173
2020
Q4
$231M Sell
6,277,451
-869,468
-12% -$31.9M 0.24% 115
2020
Q3
$249M Sell
7,146,919
-557,377
-7% -$19.5M 0.29% 79
2020
Q2
$239M Sell
7,704,296
-733,502
-9% -$24.9M 0.3% 86
2020
Q1
$261M Sell
8,437,798
-754,398
-8% -$25.7M 0.4% 52
2019
Q4
$342M Sell
9,192,196
-1,876,005
-17% -$66.8M 0.4% 47
2019
Q3
$377M Sell
11,068,201
-1,200,184
-10% -$43.6M 0.46% 35
2019
Q2
$504M Sell
12,268,385
-810,248
-6% -$32.2M 0.6% 22
2019
Q1
$527M Sell
13,078,633
-980,639
-7% -$39.3M 0.65% 20
2018
Q4
$582M Sell
14,059,272
-1,077,650
-7% -$44.7M 0.81% 9
2018
Q3
$633M Sell
15,136,922
-862,806
-5% -$33.2M 0.72% 13
2018
Q2
$551M Sell
15,999,728
-923,412
-5% -$31.6M 0.61% 20
2018
Q1
$570M Buy
16,923,140
+2,564,060
+18% +$88.1M 0.65% 18
2017
Q4
$494M Sell
14,359,080
-792,112
-5% -$27M 0.57% 22
2017
Q3
$513M Sell
15,151,192
-689,574
-4% -$22.2M 0.64% 17
2017
Q2
$505M Sell
15,840,766
-821,394
-5% -$25.9M 0.65% 16
2017
Q1
$541M Sell
16,662,160
-3,302,443
-17% -$104M 0.7% 11
2016
Q4
$615M Sell
19,964,603
-5,342,933
-21% -$163M 0.83% 7
2016
Q3
$813M Buy
25,307,536
+117,283
+0.5% +$3.92M 1.1% 2
2016
Q2
$842M Sell
25,190,253
-1,743,253
-6% -$55.6M 1.16% 2
2016
Q1
$757M Buy
26,933,506
+4,393,679
+19% +$126M 1.04% 3
2015
Q4
$690M Sell
22,539,827
-2,161,103
-9% -$68M 0.9% 3
2015
Q3
$736M Buy
24,700,930
+747,984
+3% +$24M 0.95% 3
2015
Q2
$762M Sell
23,952,946
-2,950,532
-11% -$96.2M 0.85% 6
2015
Q1
$888M Sell
26,903,478
-1,429,665
-5% -$45.5M 0.95% 4
2014
Q4
$837M Sell
28,333,143
-1,488,467
-5% -$42.7M 0.87% 7
2014
Q3
$837M Sell
29,821,610
-2,485,742
-8% -$69.8M 0.86% 10
2014
Q2
$910M Buy
32,307,352
+2,927,880
+10% +$83.5M 0.89% 9
2014
Q1
$895M Buy
29,379,472
+929,047
+3% +$27.7M 0.91% 8
2013
Q4
$827M Sell
28,450,425
-692,171
-2% -$20.1M 0.85% 11
2013
Q3
$794M Buy
29,142,596
+589,266
+2% +$16M 0.88% 7
2013
Q2
$759M Buy
+28,553,330
New +$789M 0.9% 7

Other funds holding PFE

Neuberger Berman Group's PFE Position: Q1 2026 in Review

Neuberger Berman Group increased its Pfizer (PFE) stake by 32% in Q1 2026, buying an estimated $62.1M and bringing the position to 9,693,119 shares worth $272M. The position accounts for 0.21% of the portfolio, ranked #95.

Neuberger Berman Group first reported a position in PFE in Q2 2013 and has held it in 52 quarters since. The position peaked at $910M in Q2 2014. 2,937 funds tracked by Wall St. Rank hold PFE as of Q1 2026.

  • Neuberger Berman Group held 9,693,119 shares of Pfizer worth $272M as of Q1 2026.
  • Neuberger Berman Group bought 2,331,465 Pfizer shares in Q1 2026, an estimated $62.1M.
  • Pfizer made up 0.21% of Neuberger Berman Group's portfolio in Q1 2026, its #95 holding.
  • Neuberger Berman Group first reported a position in Pfizer in Q2 2013 and has held it in 52 quarters since.
  • Neuberger Berman Group's Pfizer position peaked at $910M in Q2 2014.
  • 2,937 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.

Based on Neuberger Berman Group's 13F filing for Q1 2026, filed 14 May 2026.